Topics Related to Prescription Drugs, Anxiety
and Depression
   Home      Bio


Dr. Hughes, after receiving his Ph.D. in physical chemistry and teaching  college for several years, was employed by P&G Pharmaceuticals where he was quickly promoted and headed a group of Ph.D. scientists and associate scientists. His responsibilities included the development of analytical methods for quality control of dosage forms, stability testing, bioanalytical assays, product and raw material impurities, reference standards, and identity testing by HPLC, GC, TLC, AA, UV, fluorometric and wet chemical methods. He was involved with the development of all IND and NDA submissions while at P&G and developed the chromatographic methods for the Buprenex, Asacol, skeletal muscle relaxant, cardiotonic, and anti-arrhythmic submissions.

Dave joined the Bristol-Myers Squibb Company in 1990 and was promoted several times culminating with the title of Senior Principal Scientist, the only separation scientist at BMS promoted to that level. In addition to his scientific contributions, he was responsible for a team of (7-10) Ph.D’s and associate scientists; departmental validation coordination, and all aspects of method development for both conventional and biotechnological products. He was involved with many BMS products: Cefzil, Maxipime, Serzone, Mutamycin, Videx, and Zerit.   Dave was also heavily involved with methods development for biologics for RA, immunosuppressant therapy, and antibody/cytotoxin  conjugates as anticancer agents. He directed the creation of a GLP/GMP compliant laboratory at the  Princeton , New Jersey BMS  site and was involved with  ongoing regulatory activities including representing BMS during  FDA audits. During his tenure at Princeton, he was the recipient of the President's Award. He was the organizer and leader of the multi-site Community of Separation Sciences (2000-2003) and served as the senior collaborator on separation science issues at all BMS sites. Dr. Hughes was awarded a patent for an atropisomeric cardiovascular drug he isolated in 2002. David founded Chromatographic Excellence in 2003. He currently consults in all areas of  pharmaceutical and biotechnological analytical chemistry with special expertise in  conventional and capillary liquid chromatographic method development, capillary electrophoresis, validation, and applications.  Most recently, he has been extensively involved in capillary LC applications development for single and multi-channel instruments.








 Content on this Web site  is for informational purposes only. We do not provide any medical advice, diagnosis or treatment and direct our readers to qualified professionals for such services.  We do not accept either funding nor advertising from any source.  Our mission is solely informational and is directed toward a  non-professional audience.  Any correspondence with the owner of this site will be held in strictest confidence.